Clover Health Investments (CLOV)
(Real Time Quote from BATS)
$0.69 USD
+0.02 (2.99%)
Updated Apr 26, 2024 10:43 AM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Clover Health Investments, Corp falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,034 | 3,477 | 1,472 | 0 | 0 |
Cost Of Goods | 1,776 | 3,454 | 1,544 | 0 | 0 |
Gross Profit | 257 | 23 | -72 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 466 | 394 | 565 | 7 | 0 |
Income After Depreciation & Amortization | -209 | -371 | -637 | -7 | 0 |
Non-Operating Income | -5 | 33 | 52 | 0 | 0 |
Interest Expense | 0 | 1 | 3 | 0 | 0 |
Pretax Income | -213 | -339 | -588 | -7 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -213 | -339 | -588 | -7 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -213 | -339 | -588 | -7 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -210 | -371 | -622 | -7 | 0 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 15 | 0 | 0 |
Income After Depreciation & Amortization | -209 | -371 | -637 | -7 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 482.18 | 476.24 | 412.92 | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.41 | -0.76 | -1.09 | NA | NA |
Diluted Net EPS (GAAP) | -0.44 | -0.71 | -1.42 | -0.32 | NA |
Fiscal Year end for Clover Health Investments, Corp falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 510.25 | 482.07 | 513.63 | 527.78 |
Cost Of Goods | NA | 447.99 | 418.96 | 436.95 | 472.49 |
Gross Profit | NA | 62.27 | 63.11 | 76.67 | 55.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 127.93 | 104.58 | 105.48 | 127.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -65.66 | -41.47 | -28.81 | -72.60 |
Non-Operating Income | NA | -4.81 | 0.00 | 0.00 | 0.00 |
Interest Expense | NA | 0.00 | 0.00 | 0.01 | 0.00 |
Pretax Income | NA | -70.47 | -41.47 | -28.81 | -72.61 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -70.47 | -41.47 | -28.81 | -72.61 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -70.47 | -41.47 | -28.81 | -72.61 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 481.61 | 480.77 | 479.16 | 478.81 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.09 | -0.06 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.14 | -0.09 | -0.06 | -0.15 |